tbuckley/cabot-search huggingface dataset:
Depression, anxiety, and patterns of mental health care among men with prostate cancer on androgen deprivation therapy (ADT).
Authors: Phoebe A. Tsao, Ryan Ross, Amy S. B. Bohnert, Bhramar Mukherjee, Megan Veresh Caram
Journal: Journal of Clinical Oncology (2020)

12100 Background: ADT is associated with an increased risk of depression and anxiety, raising the concern that a substantial portion of men with prostate cancer need mental health care. We sought to investigate the development of depression or anxiety and subsequent patterns of mental health care in men with prostate cancer on ADT. Methods: Clinformatics DataMart, a claims database of commercially insured patients, was used to identify men with prostate cancer who received ADT between 2001-2015 and had continuous enrollment for 1 year before and 2 years after starting ADT. We determined the rate of incident diagnoses of depression or anxiety and the incident use of mental health treatments - psychotherapy and psychiatric medications (≥ 5 day supply) - after the start of ADT. Results: Among 37,388 men in the final analytic cohort, 11.3% (n=4239, 95% confidence interval (CI) 11.0-11.6%) received new diagnoses of depression or anxiety: 5.8% depression (95% CI, 5.5-6.0%), 3.7% anxiety (95% CI 3.5-3.9%), and 1.8% both (95% CI, 1.7-1.9%). Those who received a diagnosis of depression or anxiety were more likely to be white (68% v. 64%, p&lt;0.01); no differences were noted in age, education, or household income. Among those with a new diagnosis of depression or anxiety, 0.07% received psychotherapy (95% CI, 0.02-0.23%), 34.9% a selective serotonin reuptake inhibitor (95% CI, 33.5-36.4%), 11.6% a serotonin norepinephrine reuptake inhibitor (95% CI, 10.7-12.6%), and 19.9% a benzodiazepine (95% CI, 18.7-21.1%). Conclusions: Among men with prostate cancer receiving ADT, more than 1 in 10 received a new diagnosis of depression or anxiety. Of those, 1 in 5 were introduced to a benzodiazepine, a drug class with risks of dependence, cognitive impairment, falls, and fractures, whereas receipt of psychotherapy was rare. Further investigation into how to improve the mental health care of men on ADT is needed. [Table: see text]
Real-world outcomes after second-line treatment in non-small cell lung cancer (NSCLC) patients treated with immunotherapy.
Authors: Melina Elpi Marmarelis, Wei-Ting Hwang, Yu-Xiao Yang, Christine Agnes Ciunci, Aditi Puri Singh, Charu Aggarwal, Roger B. Cohen, Corey J. Langer, Ronac Mamtani, Joshua Bauml
Journal: Journal of Clinical Oncology (2020)

e21620 Background: In patients (pts) with advanced non-small cell lung cancer (NSCLC), national guidelines recommend against retrial of immunotherapy (IO) if there is disease progression on IO in the 1st-line (1L). However, optimal 2nd-line (2L) therapy after 1L IO remains unclear and there is significant practice variation. We compared outcomes of 2L approaches after 1L IO or chemoimmunotherapy (chemoIO). Methods: This retrospective cohort study utilized the Flatiron Health EHR-derived de-identified advanced NSCLC database. The study population included pts with disease progression on 1L IO or chemoIO and who subsequently received 2L therapy. Pts with targetable alterations were excluded. We defined the exposure by type of 2L therapy (IO, chemoIO, chemo). Multivariate covariates included age, sex, race, 1L progression-free survival (PFS) and PDL1 level. Median overall survival (mOS) and median real-world PFS (mPFS, based upon abstraction of clinician documentation) times were estimated from Kaplan-Meier curves. A multivariate Cox proportional hazard model computed hazard ratios (HRs) to assess the effectiveness of 2L treatment. Results: 532 NSCLC pts received 1L IO and a 2L therapy, of which 393 (74%) received 1L IO and 139 (26%) received 1L chemoIO. Among 1L IO patients, 2L therapies included chemo (315 (80%)), IO (39(10%), 18/39 (46%) switched IO), and chemoIO (39(10%)). Among 1L chemoIO patients, 2L therapies included: chemo (121 (87%)), IO (8(6%), 6/8 switched IO) and ChemoIO (10 (7%), 8/10 changed chemo used). All pts who received 2L ChemoIO continued the same IO agent. Demographics were well balanced between 2L groups except for higher PDL1 level in the IO-based groups and older age in the IO alone group. There was no statistically significant difference in mPFS or mOS between 2L IO and non-IO containing regimens (Table), nor were there differences among patients switching IO agents in the 2L (multivariate p interaction = 0.2 (PFS), 0.06 (OS)) (Table). Conclusions: Despite national guidelines against this practice, a small proportion of pts in routine care receive 2L IO-based therapies after disease progression on 1L IO or chemoIO. We found similar outcomes between IO and non-IO based 2L therapies after progression on 1L IO or chemoIO. [Table: see text]
浅谈新形势下高等院校全科医生的培养
Authors: 姚敏
Journal: BMJ (2008)

去年2月卫生部推出社区首诊制,以缓解群众看病难、看病贵的问题.但是一个难以回避的问题是目前为社区提供首诊医疗服务的全科医生数量和水平有限,满足不了群众的需求[1].笔者认为,在当前新形势下要培养合格的全科医生.医学高等院校在具体教学中应重点抓好以下几个环节。
The role of non-oncology specialties in the real world longitudinal journey of prostate cancer patients.
Authors: Daniel Carnegie, Elenee Argentinis, Dibyajyoti Mazumder, Indu Dhangar
Journal: Journal of Clinical Oncology (2020)

e19255 Background: Electronic health records (EHRs) are increasingly being recognized by regulators and researchers as reliable sources of evidence. It is therefore critical that real world evidence databases accurately reflect all diagnostics and interventions that could affect patient outcomes. Some of the commercially available datasets source data solely from oncology clinics, which may not reflect patients’ full care journey. This analysis assessed the contribution of non-oncology specialties to prostate cancer care. Methods: Newly diagnosed prostate cancer patients with encounters between Jan 2014 to Dec 2017 were analyzed from the deidentified Optum Electronic Health Record Data Repository. Diagnostic procedures 6 months prior to the index date (first diagnosis date within the study period) and 1 year post index date were identified. Attending physician specialties were identified. All treatment related encounters up to 1 year post the index dates were mapped by specialty. Codes were verified by certified medical professional. Results: A total of 186,299 prostate cancer patients were identified between Jan 2014 to Dec 2017. In the 6 months prior to index date, biopsy was most commonly ordered by urologists (70%), followed by surgical specialists (14%). Biomarker tests were ordered mostly by general practitioners (40%) followed by urologists (18%). The trend was similar for 1 year post biopsy and other histology procedures. Interestingly, a large portion of treatment encounters was observed outside oncology: 48% of surgical management by urologists (48%), chemotherapy was prescribed by both oncologists (27%) and urologists (31%) in a similar ratio, while radiotherapy was performed predominantly by radiation oncologists (81%). Conclusions: In prostate cancer, a large proportion of care encounters occur outside oncology specialties, with urology conducting a significant proportion of diagnostic testing and early treatment. Restricting source data to oncology specialties may omit key factors affecting patients’ outcomes, therefore data for such studies should reflect the entire care continuum.
Diagnostic value of plasma N-terminal pro brain natriuretic peptide in elderly patients with acute exacerbation of chronic obstructive pulmonary disease associated with left-heart failure
Authors: Han-xiang Nie, Yi Huang, Xu-hong Ding, Su-ping Hu
Journal: BMJ (2010)

Plasma level of N-terminal pro brain natriuretic peptide (NT-proBNP) was measured for 362 elderly patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), including 97 of AECOPD complicated with left-heart failure and 265 of isolated AECOPD.Results indicated that there was significant difference in plasma level of NT-proBNP between the two groups ( P = 0.000).With a cut-off value of 1643.5 ng/L NT-proBNP, its sensitivity, specificity and accuracy for identifying AECOPD complicated with left-heart failure in the elderly were 84.4%, 85.3% and 85.1%, respectively.It is suggested that assay for plasma NT-proBNP may be helpful to identify left-heart failure in elderly patients with AECOPD.

Key words: 
Heart failure, congestive;  Natriuretic peptide, brain
Next-generation sequencing for genetic analysis of endobronchial ultrasound transbronchial needle aspiration samples in advanced lung cancer.
Authors: Xianjun Min, Mingwei Li, Qiang Liu, Yingshun Yang, Guotian Pei, Shuai Wang, Xiaoyu Wang, Huina Wang, Feng Lou, Shanbo Cao, Jun Liu, Yuqing Huang
Journal: Journal of Clinical Oncology (2020)

e15586 Background: Next-generation sequencing (NGS) typically requires greater quantities of DNA than traditional molecular testing. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) is a minimally invasive technique with high sensitivity in the mediastinal staging of lung cancer. This study aimed to evaluate the adequacy of EBUS-TBNA in providing adequate size specimens for genetic mutations and immunotherapy biomarkers analysis in patients with lung cancer. Methods: Tissue samples from patients with advanced lung cancer were collected by EBUS-TBNA and were formalin-fixed paraffin-embedded. NGS assay was carried on with acornmed panel including 808 genes. PD-L1 expression through immunohistochemistry was assessed. Results: A total of 98 patients was enrolled, of which 74 (76%) were adenocarcinoma and 20 (20%) were squamous cell carcinomas. Among the patients, 108 samples (including multipoint puncture of different location and retest of the same patient) were obtained. NGS assay was completed successfully on 106 of the 108 samples (98.14%), and 97.96% of patients had successful testing, identifying an average of 11.3 mutations. With a multi-gene panel comprising up to 808 tumor related genes, actionable variations were found in 93 (86%) samples. Of these, the positive rates of actionable alterations in lung adenocarcinoma samples and lung squamous cell carcinoma samples were 90% and 79%, respectively. The tumor mutation burden (TMB), Microsatellite instability (MSI) and PD-L1 expression were found High in 20 (41%), 1 (2%), and 37 (72%) patients respectively. Conclusions: NGS assay can be successfully conducted with tissue samples obtained from EBUS-TBNA. NGS assay provides more comprehensive information on genetic mutations in tumors, which greatly assists therapeutic decision making for advanced lung cancer.
Covid-19: GPs angry they were not told about changes to shielding advice
Authors: Gareth Iacobucci
Journal: BMJ (2020)

The government’s sudden decision to relax its advice for patients who are most at risk from covid-19 to “shield” at home has left GP practices unprepared and vulnerable patients concerned, doctors have warned.

On Saturday 30 May, the government unexpectedly announced that 2.2 million people who had previously been told to stay at home because they were at especially high risk from covid-19 would be able to go outside with members of their household from 1 June, provided they maintained social distancing. The updated advice1 also stipulated that people who live alone can meet outside with one other person.

The sudden shift prompted a backlash from GPs, who said it had left them ill prepared for dealing with queries from anxious patients. Just two days earlier, NHS England had published revised advice for GPs stating that shielded patients should continue to stay at home, adding to the sense of confusion.2

The announcement appeared to …
POLO: Quality-adjusted (QA) progression-free survival (PFS) and patient (pt)-centered outcomes with maintenance olaparib in pts with metastatic pancreatic cancer (mPaC).
Authors: Hyun Kyoo Yoo, Hedy L. Kindler, Susan McCutcheon, David McGuinness, Nikunj Patel, Robert Hettle, Rory Goodbody, Seongjung Joo, Gershon Y. Locker, Talia Golan
Journal: Journal of Clinical Oncology (2020)

4626 Background: In the Phase III POLO trial (NCT02184195), maintenance olaparib significantly prolonged PFS vs placebo in pts with a germline BRCA1 and/or BRCA2 mutation (gBRCAm) and mPaC (median 7.4 vs. 3.8 months). The aim of maintenance treatment is to extend PFS and survival without compromising health-related quality of life due to adverse events. The duration of time spent without symptoms or toxicities (TWiST) and the QA-PFS were assessed in a post hoc analysis of the POLO trial. Methods: Patients were randomized 3:2 to receive maintenance olaparib (tablets; 300 mg bid) or placebo. Restricted mean (RM)-PFS was calculated by estimating the area under the Kaplan–Meier PFS curve between randomization and 29.8 months after randomization (maximum follow-up for the placebo arm in POLO). Patient-centered outcomes were assessed by QA-PFS (derived from the product of the EQ-5D-5L single-index utility score from randomization to disease progression and RM-PFS) and TWiST (RM-PFS minus time with toxicity after randomization). Results: RM-PFS was significantly longer with olaparib, with a between-treatment difference of 4.8 months ( P=0.009; Table). Over this period, no significant or meaningful differences in mean EQ-5D-5L index were observed between treatment groups. The corresponding mean QA-PFS was significantly longer with olaparib vs placebo. TWiST analysis demonstrated a benefit with olaparib over placebo (Table): between-arm difference, 3.8 months ( P=0.039) for the primary analysis (criteria 1: grade ≥2 nausea, vomiting or fatigue). Sensitivity analysis (criteria 1 plus abdominal pain, diarrhea, decreased appetite or constipation) also revealed a trend toward benefit with olaparib (difference: 3.4 months, P=0.062). Conclusions: Consistent with the primary PFS analysis of the POLO trial, RM-PFS and QA-PFS were significantly longer with maintenance olaparib than with placebo. As demonstrated by the findings of the TWiST analyses, the PFS benefit observed with olaparib in pts with a gBRCAm and mPaC persists even when symptoms of toxicity are considered. Clinical trial information: NCT02184195 . [Table: see text]
Role of high-dose chemotherapy with autologous stem cell transplantation for primary central nervous system lymphoma: A systematic review.
Authors: Shaha Nabeel, Zahoor Ahmed, Arafat Ali Farooqui, Zunairah Shah, Aqsa Ashraf, Hassan Imtiaz, Rabia Ashraf, Karun Neupane, Muhammad Salman Faisal, Faiz Anwer
Journal: Journal of Clinical Oncology (2020)

2562 Background: High dose chemotherapy (HDCT) followed by autologous stem cell transplant (ASCT) has shown to overcome intrinsic chemo-resistance and improve disease control in Primary Central Nervous System Lymphoma (PCNSL). Our study reviews the treatment outcome in PCNSL with sequential HDCT and ASCT. Methods: 8/34 studies were finalized after systematic search of PubMed, Cochrane, and Clinicaltrials.gov for treatment of PCNSL with HDCT followed by ASCT. Results: 251/288 patients were evaluated. Mean age was 55.5 years. 227 underwent HDCT-ASCT. 174 were newly diagnosed (ND) and 77 had relapsed refractory (R/R) PCNSL. ND patients showed superior outcomes in terms of progression free survival and overall survival. Combinations of High dose Rituximab, Busulfan and Cyclophosphamide significantly improved survival outcomes in RR patients. Significant toxicities mainly included pancytopenias and opportunistic. Conclusions: Primary CNS lymphoma treated with HDCT followed by ASCT has shown promising outcomes and has set a benchmark for future studies. [Table: see text]
Important lessons learned from studies on the pharmacology of glucocorticoids in human airway smooth muscle cells: Too much of a good thing may be a problem
Authors: Yassine Amrani, Reynold A. Panettieri, Patricia Ramos-Ramirez, Dedmer Schaafsma, Klaudia Kaczmarek, Omar Tliba
Journal: Pharmacology & Therapeutics (2020)
The new community mental health characteristics under the new situation
Authors: 甘一方
Journal: BMJ (2009)

随着我国医疗改革,特别是社区医疗服务体制的进一步完善以及各项社区医疗工作的不断深入开展,如今,社区医疗卫生工作已进入了全面发展的阶段,而作为社区医疗卫生工作重要内容之一的社区精神卫生服务不仅已逐步纳入全科医师的日常工作,同样亦面临着新的形势,并在新形势下出现了新的特点,迎来了新的发展机遇和挑战。
An unexpected diagnosis of undetermined biliary stenosis via endoscopic ultrasound
Authors: Jérémie Albouys, Sophie Geyl, Rebecca Rodrigues, Véronique Loustaud-Ratti, Romain Legros, Mathieu Pioche, Jérémie Jacques
Journal: Endoscopy (2020)

Endoscopic diagnosis of indeterminate biliary stenosis is difficult, often requiring repeat examinations [1]. Among rare causes of such stenoses, portal biliopathy is exceptional; 65 – 85 % of patients with extrahepatic portal obstructions exhibit no symptoms [2] [3]. Physiopathologically, the condition is caused by dilation of both plexuses that return the blood of the main bile duct. This develops secondarily to portal hypertension and compresses the common bile duct.
Significance of Inter aorto-caval lymph nodes in gall bladder cancer management.
Authors: Kishore Singh, Anurita Srivastava, Siddharth Srivastava, Aditi Aggarwal, Varshu Goel, Arun Kumar Rathi, Sundeep Saluja, Pooja Sakhuja
Journal: Journal of Clinical Oncology (2020)

e16607 Background: Gallbladder cancer (GBC) is one of the three leading cancer among women of North and North-east India. The age standardized rate (ASR) for GBC in women of North and north-east India are 11.8/100,000 population and 17.1/100,000 population respectively It is one of the most fatal cancer, characterized by early spread, both local as well as distant. Radical resection is associated with the highest control rates. Presence of inter-aorto-caval lymph nodes (IAC) during preoperative workup is designated as metastatic disease in GBC and radical surgery is deferred. This study attempts to confirm the validity of such an approach. Methods: Between January 2017 and December 2018, 178 patients of GBC were registered at our hospital. Of these, 108 patients with radiologically resectable disease were evaluated preoperatively with endoscopic ultrasound (EUS) to look for IAC lymph nodes lying below the level of the renal vein. Patients with IAC involvement were taken up for chemotherapy while the others underwent upfront surgery. Results: Mean age at presentation was 51.1 (±10.9) years with a female predominance (N = 77, 71.2%). Presenting symptoms were either pain (N = 91, 84.2%) or jaundice (N = 42, 38.8%) in majority cases. Patients with jaundice presented earlier with mean of 53.27 days (Range2-240 days) while those with pain presented at a mean of 71.5 days (1-360 days) prior to diagnosis. Pathologically positive IAC cases (n = 12) of resectable GBC received systemic therapy upfront rather than immediate radical surgery. Rest of the patients underwent surgical resection followed by adjuvant treatment as indicated. Mean follow up was 179 days with a mortality of 62%(n = 67). No significant difference was seen in the stage distribution in IAC positive versus negative group. Median survival with Kaplan Meier method of IAC positive patients was 239 days versus 190 days in IAC negative patients. Conclusions: IAC lymph node may not necessarily portend poor prognosis. It needs to be validated in large sample size.
Molecular determinants of prostate specific antigen (PSA) kinetics and clinical response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in SPARTAN.
Authors: Fred Saad, Julie N Graff, Boris A. Hadaschik, Stephane Oudard, Paul N. Mainwaring, Amitabha Bhaumik, Michael Gormley, Anil Londhe, Shibu Thomas, Angela Lopez-Gitlitz, Suneel Mundle, Elai Davicioni, Eric Jay Small, Matthew Raymond Smith, Felix Y Feng
Journal: Journal of Clinical Oncology (2020)

5521 Background: In SPARTAN, APA + androgen deprivation therapy (ADT) prolonged metastasis-free survival (MFS) and improved PSA kinetics over placebo (PBO) + ADT in high-risk nmCRPC. All molecular subtypes derived benefit in MFS from APA (Feng FY, et al. ASCO GU 2019; abstract 42). We evaluated the association of PSA decline and efficacy outcomes in SPARTAN pts with different molecular subtypes. Methods: Gene expression from archival primary tumors (biomarker population) was assessed with the DECIPHER platform (Decipher Biosciences, Inc.) and stratified into genomic classifier (GC) high- and low-to-average risk using GC score &gt; 0.6 and ≤ 0.6, respectively, and ADT-resistant or -sensitive basal or luminal A/B (PAM50 classifier) subtypes. PSA nadir and confirmed PSA decline (Table) were assessed in APA pts overall and at 3, 6, and 12 mo. Associations between molecular subtypes and outcomes were assessed. Results: Of 233 available samples, 154 were from APA pts; 49% of APA pts had high GC score and 66% had basal subtype. PSA levels at baseline were similar across all subtypes. Regardless of GC score or basal/luminal subtype, &gt; 50% of patients achieved ≥ 90% reduction in PSA with APA. PSA declined faster and PSA reduction was deeper at 6 mo (Table) in GC low to average vs GC high risk and luminal vs basal subtypes. Overall, only luminal vs basal subtypes had a significantly higher % of pts with ≥ 90% PSA decline (Chi square p = 0.037). In luminal pts, deeper PSA decline with APA was consistent with improved MFS vs basal pts. In GC high pts, MFS benefit with APA was similar to that in GC low to average pts despite lower PSA decline. Although GC low to average and luminal pts had more rapid and deeper PSA responses than GC high or basal pts, respectively, all pts derived MFS benefit. Association of long-term outcomes with PSA decline in these molecular subtypes will be presented. Conclusions: In SPARTAN, all molecular subtypes of pts with nmCRPC treated with APA + ADT had MFS benefit and rapid and sustained PSA decline. PSA responses were deepest and most rapid in GC low to average and luminal subtypes. Clinical trial information: NCT01946204 . [Table: see text]
Association of fatty pancreas with increased risk of pancreatic adenocarcinoma.
Authors: Bara El Kurdi, Adam Bataineh, Sumbal Babar, Mahmoud El Iskandarani, Mohammad Alomari, Anas Albawaliz, Madhusudhan Sanaka
Journal: Journal of Clinical Oncology (2020)

e16729 Background: Pancreatic adenocarcinoma (PADC) remains one of the most fatal malignancies with poor outcomes and prognosis. Several risk factors have been associated with its development such as smoking, age, obesity, chronic pancreatitis, diabetes mellitus and a family history of PADC. Furthermore, recent pathologic studies demonstrated that fatty infiltration of the pancreas (FP) is positively correlated with PADC development. We sought to systematically review the literature and perform the first meta-analysis to study the risk of PADC among patients with FP. Methods: We conducted a systematic search of the Pubmed, EMBASE, and Cochrane databases from inception through November-2019 for studies correlating FP with PADC. Relevant data was extracted and analyzed using comprehensive meta-analysis software. Random-effects model was used for all variables. Heterogeneity was assessed using the I 2 measure and Cochrane Q-statistic. Publication bias was assessed using Egger’s test. Meta regression models accounting for independent variables such as age, sex, smoking, family history of PADC, chronic pancreatitis and method of FP diagnosis were constructed to explain heterogeneity. Results: Five observational case-control studies published between 2014 and 2019 including a total of 761 patients (320 PADC patients and 441 controls) were included. FP was associated with increased PADC with an OR 4.6 (CI 2.4-8.9) compared to controls with a considerable heterogeneity (I 2 = 69%). Meta regression analysis accounting for modality used to diagnose FP was able to explain 100% of the noted heterogeneity. Conclusions: While we noted FP to be significantly associated with increased PADC, heterogeneity in FP diagnostic approach resulted in significant inter-study variation. A consensus on a clear definition of FP with a standardized diagnostic approach is needed to better appraise literature on this emerging disease entity. Further prospective studies are needed to validate our results and explore the possible role for PADC screening in FP in addition to known factors such as family history and new-onset diabetes mellitus.